Metformin + TOTUM-63 Combination: VALBIOTIS Announces First Preclinical Data for Possible Use in Diabetes Real Life Practice
December 04 2017 - 11:35AM
Business Wire
∙ No risk of hypoglycemia for the metformin +
TOTUM-63 combination shown in preclinical studies
∙ First positive preclinical results on
insulinemia, during an oral glucose tolerance test
Regulatory News:
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171204005448/en/
(Graphic: VALBIOTIS)
VALBIOTIS (Paris:AVAL) (FR0013254851 – ALVAL / PEA/PME
eligible [the PEA-PME scheme is a share savings plan aimed at
providing financing aid to SMEs]), a company specialized in the
development of innovative nutrition solutions designed to prevent
cardiometabolic diseases and provide nutritional support for
patients, today announces initial positive preclinical data on the
combination of metformin with TOTUM-63, for possible use in
diabetes real life practice. These results were selected and will
be presented during the annual congress of the International
Diabetes Federation in Abu Dhabi (UAE) on December 5, 2017.
Metformin is considered as the first-line standard treatment
prescribed for newly diagnosed type 2 diabetic patients. This
medication belongs to the class of oral antidiabetic drugs and is
used to normalize fasting glycemia by increasing insulin
sensitivity and by reducing neoglucogenesis (production of glucose
by the liver).
> Metformin as a possible combination: an additional asset
for the use of VALEDIA® in real life practice
While the safety of TOTUM-63 alone has already been proven,
VALBIOTIS provides new data for the active ingredient of VALEDIA®
in order to supply all the necessary data for patients and
healthcare professionals to use this product in real life. Tested
in combination with metformin in murine models (C57BL6/J), TOTUM-63
has not demonstrated any risk of hypoglycemia.
Furthermore, initial data in these murine models suggest a
beneficial potentiating effect of TOTUM-63 on the reduction of
insulinemia induced by metformin, in response to an oral glucose
tolerance test (Fig. 1).
Figure 1: Insulinemic response in murine models during an
oral glucose tolerance test (OGTT) after 16 weeks of
complementation with metformin, alone or in combination with
TOTUM-63 (*p <0.05).
OGTT: Oral glucose tolerance testAUC: Area under
curveHFD: High-fat diet
These favorable initial results pave the way for a clinical
trial in type 2 diabetic patients treated with metformin, which
will provide all the necessary data for an optimal use of VALEDIA®
in current diabetes practice.
ABOUT VALBIOTIS
VALBIOTIS specializes in developing innovative nutrition
solutions designed to prevent cardiometabolic diseases and provide
nutritional support for patients. Its products are made for
manufacturers in the agri-food and pharmaceutical industries.
VALBIOTIS particularly focuses on solutions to prevent type 2
diabetes, NASH (nonalcoholic steatohepatitis), obesity and
cardiovascular diseases.
VALBIOTIS was founded in La Rochelle in early 2014 and has
formed numerous partnerships with top academic centers in France
and abroad, including the La Rochelle University, the CNRS and the
Clermont Auvergne University located in Clermont-Ferrand, where the
company opened a second office. These agreements enable it to
benefit from a considerable leverage effect since it was set up
thanks, in particular, to the experts and technical partners
mobilized for these projects. VALBIOTIS is a member of the “BPI
Excellence” network and received the “Innovative Company” status
accorded by BPI France. Valbiotis has also been awarded “Young
Innovative Company” status and has received major financial support
from the European Union for its research programs by obtaining
support from the European Regional Development Fund (ERDF).
Find out more about
VALBIOTIS:http://valbiotis.com/
Name: VALBIOTISISIN code:
FR0013254851Mnemonic code: ALVAL
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171204005448/en/
FINANCIAL COMMUNICATIONACTIFINStéphane RUIZ, +33 1 56 88
11 14sruiz@actifin.frorPRESS RELATIONSALIZE PRCaroline
CARMAGNOL / Wendy RIGAL+33 1 44 54 36
66valbiotis@alizerp.comorCOMMUNICATION
DEPARTMENTVALBIOTISMarc DELAUNAY, +33 5 46 28 62
58marc.delaunay@valbiotis.com
Grupo Aval Acciones y Va... (NYSE:AVAL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Grupo Aval Acciones y Va... (NYSE:AVAL)
Historical Stock Chart
From Apr 2023 to Apr 2024